Compare Neurocrine Biosciences Inc (NBIX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Verizon Communications Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Verizon Communications Inc trades at $49.79 (market cap $209.44B). The key difference: Verizon Communications Inc is far larger — about 13.3× Neurocrine Biosciences Inc's market cap, and Verizon Communications Inc pays a 5.61% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | VZ | |
|---|---|---|
Market Cap | $15.77B | $209.44B |
Sector | Health | Media |
52-Week High | $185.50 | $51.38 |
52-Week Low | $123.10 | $38.40 |
Enterprise Value | $15.78B | $396.15B |
Volume | — | 22,584,735 |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Verizon (VZ) trades at $50.41, up 0.54% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock offers a 5%+ dividend yield, supported by strong cash flow and a P/E of 13.13. Recent news highlights growth in broadband and AI infrastructure, including a multi-billion dollar fiber deal with Corning.
Outlook is positive with cost discipline and shareholder returns, but risks include high debt and competitive pressures. Analysts are mixed with a $49.69 consensus target, slightly below current price, indicating cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
